Dexcom Inc at Piper Sandler Healthcare Conference Transcript

Nov 30, 2022 / 01:30PM GMT
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research Analyst

All right. Morning, everybody. Thanks so much for joining us. I'm Matt O'Brien. I'm a med tech analyst here at Piper. I'm really excited to have the Dexcom team with us today. From the company is Matt Dolan. He's the Executive Vice President, Corporate Strategy and Business Development; and then Sean as well -- Christensen, who's Head of IR, and then I think he's just got a new FP&A rule as well. So thanks for making the Cross-country trip over. I really do appreciate it.

Matthew Dolan - DexCom, Inc. - EVP of Strategy, Corporate Development & Dexcom Labs

Thanks for having us. It's good to be here in person again, and here this time of the year, it's beautiful.

Questions and Answers:

Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research Analyst

Yes, I couldn't be more excited to be in person. 100% agree with that. So let me get
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot